Cellares is the first Integrated Development and Manufacturing Organization (IDMO), using an Industry 4.0 approach to mass-manufacture cell therapies. Its Cell Shuttle platform automates and scales the production of CAR-T and other cell therapies, serving clinical and commercial-stage developers.
Company Info
Funding & Investor Relations
Not publicly disclosed
Upcoming Milestones & Key Dates
Series D expansion ($50M)
New Bridgewater, NJ site opening
First commercial-scale production run for partner CAR-T
Clinical Development Pipeline
Recent News
A new market report finds Cellares and Ori Biotech dominate the automated cell therapy manufacturing space as CAR-T and TCR therapy developers seek scalable, GMP-grade production platforms.
News briefing: Novo Nordisk expands manufacturing in China and Czech Republic while Cellares boosts its Series D by $50M as cell therapy manufacturers continue to attract strong investor interest.
Leadership Team
Co-Founder & CEO
Co-Founder & Chief Business Officer
Co-Founder & CTO
Careers & Job Openings